About enGene, Inc.enGene Inc., based in Montréal, QC, has developed a highly flexible nucleotide (DNA and RNAi) delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels. Our platform technology has the ability to significantly impact diseases of mucosal tissues such as the gastrointestinal tract, lung and bladder as well as provide systemic release of proteins from the gut to treat diabetes, anemia, hemophilia and others.
CEO: Anthony Cheung
CMO: Theresa Podrebarac
CTO: Victor Knopov
CFO: Michele Jemus
Please click here for enGene job opportunities.
Tweets by Amgen
29 articles with enGene, Inc.
enGene Announces First-in-Human Dosing of EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial
enGene Inc., a clinical-stage biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced the dosing of the first patient in the LEGEND study, a first-in-human Phase 1/2 clinical trial of EG-70 in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
enGene Receives Fast Track Designation for EG-70 for the Treatment of Non-Muscle Invasive Bladder Cancer
enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to enGene for EG-70,
enGene Announces FDA Clearance of IND Application for EG-70, an intravesical dual-immune modulator for the treatment of non-muscle invasive bladder cancer
enGene Inc. announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for EG-70, a first-in-class non-viral gene therapy for the expression of innate and adaptive immune system activators circumscribed to the bladder.
enGene Receives Funding Through Cystic Fibrosis Foundation's Path to a Cure for the Discovery of Novel Gene Therapies to Treat Cystic Fibrosis
enGene Inc., a biotechnology company developing non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, announced today an award from the Cystic Fibrosis Foundation for the discovery of genetic medicines to treat patients with cystic fibrosis (CF).
enGene Inc. announced the appointment of José M. Lora, PhD, as Chief Scientific Officer.
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
enGene Appoints Veteran Life Sciences Executive Jason D. Hanson as Chief Executive Officer and President
enGene Inc. announced the appointment of Jason D. Hanson as President, Chief Executive Officer and Director.
enGene, Inc.'s Mucosal Gene Delivery Platform Is Successful In Targeting PD-L1 Expression In The Gut, Demonstrating Effective Treatment Of Colitis And Gvhd In Preclinical Models
Takeda And enGene, Inc. Establish Strategic Alliance To Develop Novel Therapeutics For Gastrointestinal Diseases
Forbion Capital Partners Leads CAD 13.5 Million (EUR 9.6 Million) Series B Financing Round For enGene, Inc.